Last reviewed · How we verify
intravenous & intramuscular oxytocin
At a glance
| Generic name | intravenous & intramuscular oxytocin |
|---|---|
| Also known as | Postuitrin |
| Sponsor | Etlik Zubeyde Hanim Womens' Health and Teaching Hospital |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prophylactic Regimen of Intravenous Oxytocin, Intravenous Tranexamic Acid, and Intramuscular Ergot Derivative for Primary Prevention of Postpartum Hemorrhage in Intrapartum Cesarean Section Versus Intravenous Carbetocin Alone (NA)
- A Trial of Sublingual Misoprostol to Reduce Primary Postpartum Haemorrhage After Vaginal Delivery (PHASE4)
- Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress (NA)
- Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women (PHASE1)
- Effects of Oxytocin and Carbetocin on Renal System in Cesarean Sections
- IV Versus IM Administration of Oxytocin for Postpartum Bleeding (PHASE4)
- A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (PHASE1)
- IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: